Wrapmanager Inc. Sells 648 Shares of Omnicell, Inc. (NASDAQ:OMCL)
Wrapmanager Inc. lessened its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 13.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,045 shares of the company’s stock after selling 648 shares during the quarter. Wrapmanager Inc.’s holdings in Omnicell were worth $348,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Whittier Trust Co. bought a new position in shares of Omnicell during the 2nd quarter worth approximately $26,000. Parallel Advisors LLC bought a new position in shares of Omnicell during the 1st quarter worth approximately $28,000. Nisa Investment Advisors LLC grew its position in Omnicell by 125.0% during the 1st quarter. Nisa Investment Advisors LLC now owns 540 shares of the company’s stock worth $44,000 after purchasing an additional 300 shares during the last quarter. Manchester Capital Management LLC purchased a new stake in Omnicell during the 1st quarter worth approximately $49,000. Finally, Financial Gravity Wealth Inc. purchased a new stake in Omnicell during the 1st quarter worth approximately $50,000. Hedge funds and other institutional investors own 95.93% of the company’s stock.
Several research firms have weighed in on OMCL. Zacks Investment Research raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $79.00 target price on the stock in a research report on Monday, July 29th. ValuEngine downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 12th. TheStreet downgraded shares of Omnicell from a “b” rating to a “c+” rating in a research report on Thursday, April 25th. BidaskClub downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Thursday, June 27th. Finally, Craig Hallum raised shares of Omnicell from a “hold” rating to a “buy” rating and set a $85.00 target price on the stock in a research report on Friday, July 26th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Omnicell currently has an average rating of “Buy” and an average target price of $79.11.
Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.47 by $0.04. The business had revenue of $217.40 million for the quarter, compared to the consensus estimate of $214.13 million. Omnicell had a net margin of 5.70% and a return on equity of 11.85%. The business’s revenue for the quarter was up 15.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.46 EPS. Research analysts expect that Omnicell, Inc. will post 2.05 EPS for the current year.
In other news, insider Joseph Brian Spears sold 6,450 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $79.62, for a total value of $513,549.00. Following the sale, the insider now directly owns 19,112 shares of the company’s stock, valued at approximately $1,521,697.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Dan S. Johnston sold 9,929 shares of the company’s stock in a transaction on Friday, June 28th. The shares were sold at an average price of $85.47, for a total transaction of $848,631.63. Following the completion of the sale, the executive vice president now directly owns 31,505 shares in the company, valued at $2,692,732.35. The disclosure for this sale can be found here. Insiders sold a total of 28,077 shares of company stock worth $2,287,265 over the last ninety days. Insiders own 2.77% of the company’s stock.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.